Cargando…

Targeting HER2 expression in cancer: New drugs and new indications

Functional activation of human epidermal growth factor receptor 2 (HER2) has been shown to strongly promote carcinogenesis, leading to the investigation of HER2-directed agents in cancers with HER2 genomic alterations. This has been best documented in the context of HER2 gene amplification in breast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vranić, Semir, Bešlija, Semir, Gatalica, Zoran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7861626/ https://www.ncbi.nlm.nih.gov/pubmed/32530388 http://dx.doi.org/10.17305/bjbms.2020.4908

Ejemplares similares

Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers
por: Vranic, Semir, et al.
Publicado: (2022)

PD-L1 testing by immunohistochemistry in immuno-oncology
por: Vranic, Semir, et al.
Publicado: (2023)

Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group
por: Vranic, Semir, et al.
Publicado: (2022)

HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome
por: Skenderi, Faruk, et al.
Publicado: (2022)

An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy
por: Fojnica, Adnan, et al.
Publicado: (2023)

Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast
por: Vranic, Semir, et al.
Publicado: (2020)

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies
por: Willenbacher, Wolfgang, et al.
Publicado: (2018)

Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix
por: Cimic, Adela, et al.
Publicado: (2021)

High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine
por: Gatalica, Zoran, et al.
Publicado: (2016)

NUTM1-Rearranged Neoplasms—A Heterogeneous Group of Primitive Tumors with Expanding Spectrum of Histology and Molecular Alterations—An Updated Review
por: Luo, Wenyi, et al.
Publicado: (2021)

Managing an oncology clinic during the COVID-19 pandemic—how we did it in Sarajevo?
por: Beslija, Semir
Publicado: (2020)

Acinic cell carcinoma of the breast: A comprehensive review
por: Ajkunic, Azra, et al.
Publicado: (2022)

Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets
por: Gupta, Ishita, et al.
Publicado: (2020)

Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas
por: Topcagic, Jasmina, et al.
Publicado: (2018)

A Positive Feedback Loop of ER-α36/EGFR Promotes Malignant Growth of ER-negative Breast Cancer Cells
por: Zhang, XianTian, et al.
Publicado: (2010)

Theranostic molecular profiling of pleomorphic ductal carcinoma of the breast
por: Vranic, Semir, et al.
Publicado: (2018)

Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: Analysis of 1806 cases
por: Gatalica, Zoran, et al.
Publicado: (2014)

Novel targetable biomarkers in clear cell carcinoma of the breast uncovered by molecular profiling: A study of nine cases
por: Skenderi, Faruk, et al.
Publicado: (2020)

Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling
por: Gargano, Stacey M., et al.
Publicado: (2019)

Hamartomas, teratomas and teratocarcinosarcomas of the head and neck: Report of 3 new cases with clinico-pathologic correlation, cytogenetic analysis, and review of the literature
por: Vranic, Semir, et al.
Publicado: (2008)

Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models
por: Padmanabhan, Regina, et al.
Publicado: (2020)

Infarcted fibroadenoma of the breast: report of two new cases with review of the literature
por: Skenderi, Faruk, et al.
Publicado: (2013)

Assay‐agnostic spatial profiling detects tumor microenvironment signatures: new diagnostic insights for triple‐negative breast cancer
por: Ziegler, Colleen, et al.
Publicado: (2023)

PD-L1 Status in Refractory Lymphomas
por: Vranic, Semir, et al.
Publicado: (2016)

Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
por: Sareyeldin, Rasha M., et al.
Publicado: (2019)

Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes
por: Vranic, Semir
Publicado: (2023)

Comprehensive genomic profiling of a metastatic small cell lung carcinoma with a complete and long-term response to atezolizumab: A case report
por: Tomic, Kresimir, et al.
Publicado: (2023)

Comparative analysis of the access to health-care services and breast cancer therapy in 10 Eastern European countries
por: Dimitrova, Maria, et al.
Publicado: (2020)

Comparison of the biomarkers for targeted therapies in primary extra‐mammary and mammary Paget's disease
por: Gatalica, Zoran, et al.
Publicado: (2020)

Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1
por: Gatalica, Zoran, et al.
Publicado: (2015)

Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer
por: Zielinski, Christoph, et al.
Publicado: (2016)

Elaeagnus angustifolia Plant Extract Inhibits Epithelial-Mesenchymal Transition and Induces Apoptosis via HER2 Inactivation and JNK Pathway in HER2-Positive Breast Cancer Cells
por: Jabeen, Ayesha, et al.
Publicado: (2020)

Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1
por: Joneja, Upasana, et al.
Publicado: (2017)

Differences in Outcomes Between Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Patients in Upper Middle-Income versus High-Income Countries: A Retrospective Study from 4 Oncology Centers
por: Miletić, Dragana, et al.
Publicado: (2023)

Statistical Modeling of Relations Between PET/CT Parameters and CEA in Recurrent and Metastatic Colorectal Cancer
por: Milardovic, Renata, et al.
Publicado: (2023)

TERT Gene Fusions Characterize a Subset of Metastatic Leydig Cell Tumors
por: Kruslin, Bozo, et al.
Publicado: (2021)

Quantification of the growth suppression of HER2+ breast cancer colonies under the effect of trastuzumab and PD-1/PD-L1 inhibitor
por: Padmanabhan, Regina, et al.
Publicado: (2022)

New insight into the role of PTCH1 protein in serous ovarian carcinomas
por: Karin-Kujundzic, Valentina, et al.
Publicado: (2022)

SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities
por: Gupta, Ishita, et al.
Publicado: (2020)

Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
por: Tarantino, Paolo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lofarmhmbmu3bq1o094qpnh3kl